Natco stock rides Copaxone generic 'probability' wave
This article was originally published in Scrip
Executive Summary
Pure speculation or some substance no one seemed very sure, but shares of Natco surged to a 52-week high on Indian bourses amid expectations that new launches in the US, including a much awaited generic version of Teva's multiple sclerosis blockbuster Copaxone (glatiramer acetate), would power the Indian firm's sales during the year.